A freshly-approved coronavirus vaccine from Novavax (Nasdaq: NVAX) has scored highly in a Phase III trial measuring effectiveness in adolescents aged 12 to 17.
NVX-CoV2373, which is being offered under the brand name Nuvaxovid in Europe, is a recombinant nanoparticle protein-based vaccine.
The latest data from the PREVENT-19 study, which enrolled 2,247 adolescents in the USA, show 90.4% efficacy overall and a reassuring safety and tolerability profile for the jab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze